Clinical Trials

88 enrolled

Liver Neoplasms

NCT05333458 2026-03-19

Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial

Phase 2 Recruiting

27 enrolled

Sarcoma

Sarcoma, Alveolar Soft Part

NCT05411081 2026-03-19

Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

200 enrolled

Carcinoma, Renal Cell

NCT03237780 2026-03-18

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

72 enrolled

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT04981509 2026-03-18

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Phase 2 Recruiting

65 enrolled

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT04310020 2026-03-17

Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

47 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04458922 2026-03-17

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

27 enrolled 16 charts

LymphoidSarcoma

Lymphoma, Follicular, Sarcoma, Clear Cell

NCT06161532 2026-03-17

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

Phase 2 Recruiting

60 enrolled

Carcinoma, Transitional Cell

NCT06603818 2026-02-19

Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

Phase 2 Withdrawn

Colorectal Neoplasms

NCT05836584 2025-12-01

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

240 enrolled

Clinical Stage I Gastric Cancer AJCC v8

NCT05715281 2025-11-25

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

12 enrolled

Other solid neoplasm

Advanced Rare Malignant Solid Neoplasm

NCT02849496 2025-11-24

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

81 enrolled

Breast

Breast Neoplasms

NCT05564416 2025-10-21

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

Phase 2 Withdrawn

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04729959 2025-10-20

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

59 enrolled

CNS

Astrocytoma, Glioblastoma

NCT02883062 2025-10-16

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

67 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03141684 2025-10-08

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

63 enrolled 1 FDA

Sarcoma

Sarcoma, Alveolar Soft Part

NCT03600701 2025-10-07

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

51 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02844816 2025-05-22

Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

172 enrolled 16 charts

Recurrent Bladder Urothelial Carcinoma

NCT06328036 2024-12-30

Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

Phase 2 Withdrawn

CNS

Glioblastoma

NCT03513952 2024-07-26

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

47 enrolled 14 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03201458 2024-04-05

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

86 enrolled 16 charts

Gallbladder Neoplasms, Cholangiocarcinoma

NCT02921269 2023-02-21

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer